Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: A case-control study

Clinical Infectious Diseases

Volumn 45, Issue 7, 2007, Pages

  Peñaranda Vera, Maria ^a   Falco, Vicenç ^d   Payeras, Antoni ^b   Jordano, Queralt ^c   Curran, Adria ^d   Pareja, Antoni ^b   Samperiz, Gloria ^a   Dalmau, David ^c   Ribera, Esteve ^d   Riera, Melcior ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b HOSPITAL SON LLÀTZER   (Spain)

^c Mutua de Terrasa   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE PNEUMOCOCCAL VACCINE; UNCLASSIFIED DRUG; ANTIRETROVIRUS AGENT;

ADULT; ALCOHOLISM; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG ABUSE; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INVASIVE PNEUMOCOCCAL DISEASE; LIVER CIRRHOSIS; LOBAR PNEUMONIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VIRUS LOAD; CLINICAL TRIAL; IMMUNOLOGY; MULTICENTER STUDY; SPAIN; TREATMENT OUTCOME;

ADULT; ANTI-RETROVIRAL AGENTS; CASE-CONTROL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME;

EID: 34848846869     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520977     Document Type: Article

References (35)

1. Kohli R, Lo Y, Homel P, et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis 2006; 43:90-8.
2. Wolff AJ, O'Donnell AE. Pulmonary manifestations of HIV-infection in the era of highly active antiretroviral therapy. Chest 2001; 120:1888-93.
3. Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 2000; 132:182-90.
4. Falcó V, Fernandez de Sevilla T, Alegre J, et al. Bacterial pneumonia in HIV-infected patients: a prospective study of 68 episodes. Eur Respir J 1994; 7:235-9.
5. Heffernan RT, Barrett NL, Gallagher KM, et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005; 191:2038-45.
6. Redd SC, Rutherford GW, Sande MA, et al. The role of human immunodeficiency virus infection in pneumococcal bacteraemia in San Francisco residents. J Infect Dis 1990; 162:1012-7.
7. Dworkin MS, Ward JW, Hanson DL, Lones JL, Kaplan JE; the Adult and Adolescent Spectrum of HIV Disease Project. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001; 32:794-800.
8. Gebo KA, Moore RD, Keruly JC, Chaisson RE. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173:857-62.
9. Grau I, Pallares R, Tubau F, et al. Epidemiologic changes in bacteraemic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005; 165:1533-40.
10. Feikin DR, Feldman C, Schuchat A, Janoff EN. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis 2004; 4:445-55.
11. Barry PM, Zetola N, Keruly JC, Moore RD, Gebo KA, Lucas GM. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003. AIDS 2006; 20:437-44.
12. Jordano Q, Falcó V, Almirante B, et al. Invasive pneumococcal disease in HIV-infected patients: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38:1623-8.
13. Guerrero M, Krueger S, Saitho A, et al. Pneumonia in HIV infected patients: a case-control study of factors involved in risk and prevention. AIDS 1999; 13:1971-5.
14. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons 2002: recommendations of the US Public Health Service and the Infectious Diseases Society of America. US Public Health Service/ Infectious Diseases Society of America. Ann Intern Med 2002; 137:435-78.
15. Lindenburg CE, Langendam MW, Benthem BH, Miedema F, Coutinho RA. No evidence that vaccination with a polysaccharide pneumococcal vaccine protects drug users against all-cause pneumonia. AIDS 2001; 15:1315-7.
16. Breiman RF, Keller DW, Phelan MA, et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000; 160:2633-8.
17. French N, Nakiyingi J, Carpenter LM, et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355:2106-11.
18. Pierce AB, Hoy JF. Is the recommendation for pneumococcal vaccination of HIV-patients evidence based? J Clin Virol 2001; 22:255-61.
19. Kyaw MH, Rose CE, Fry AM, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 2005; 192:377-86.
20. Domínguez A, Salleras L, Fedson DS, et al. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study. Clin Infect Dis 2005; 40:1250-7.
21. Amendola A, Tanzi E, Zappa A, et al. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-infected former drug users. Vaccine 2002; 20:3720-4.
22. Janoff EN, Douglas JM Jr, Gabriel M, et al. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1. J infect Dis 1988; 158:983-90.
23. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine 2000; 19:886-94.
24. Rodriguez-Barradas MC, Alexandraki I, Nazir T, et al. Response to human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis 2003; 37:438-47.
25. Payeras A, Martínez P, Mila J, et al. Risk factors in HIV-1-infected patients developing repetitive bacterial infections: toxicological, clinical, specific antibody class responses, opsonophagocytosis and Fcg RIIa polymorphism characteristics. Clin Exp Immunol 2002; 130:271-8.
26. Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalised adults with community-acquired pneumonia. Clin Infect Dis 2006; 42:1093-101.
27. Hung CC, Chen MY, Hsieh SM, et al. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine 2004; 22:2006-12.
28. Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med 1995; 332:1280-4.
29. Tasker SA, Wallace MR, Jeffrey BR, Pastón WB, O'Brien J, Janoff EN. Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses. Clin Infect Dis 2002; 34:813-21.
30. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354:1455-63.
31. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006; 295:1168-74.
32. Whitney CG, Farley MM, Handler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46.
33. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults on the era of paediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-51.
34. Flanery B, Hefferman RT, Harrison LH, et al. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med 2006; 144:1-9.
35. Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV infected adults. Vaccine 2001; 20:545-53.